Latest colitis Stories
October’s cannabinoid science roundup on the Bryan William Brickner Blog highlights new National Institutes of Health (PubMed) research.
FREIBURG and HEIDELBERG, Germany, October 29, 2014 /PRNewswire/ -- Positive FDA feedback on the protocol for the US Phase III trial with LT-02,
LA JOLLA, Calif., and JUPITER, Fla., Oct.
"Get Your Full Course" addresses diet and nutritional considerations related to inflammatory bowel diseases and highlights Sunny's personal story of living with ulcerative colitis HORSHAM,
Immune Pharmaceuticals Recently Initiated Phase II Clinical Trial in Ulcerative Colitis CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Oct.
PREPOPIK a prescription bowel prep for colonoscopy offers the lowest volume of active prep solution -- only 10 ounces PARSIPPANY, N.J., Oct.
First rapid test to distinguish between pathogenic and non-pathogenic species WALTHAM, Mass., Oct. 2, 2014 /PRNewswire/ -- Alere Inc.
Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Sept. 18, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc.
NEW YORK, Aug.
Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...
- A volcanic mudflow.